Today: 9 June 2026
Rolls-Royce stock at fresh 52-week high: buyback, Istanbul engine hub and UK SMR plans in focus
10 January 2026
2 mins read

Rolls-Royce stock at fresh 52-week high: buyback, Istanbul engine hub and UK SMR plans in focus

London, Jan 10, 2026, 07:54 GMT — Market closed

  • Rolls-Royce shares ended Friday up 1.65% at 1,293.5 pence, a new 52-week high.
  • The company broke ground on a new Trent engine maintenance centre with Turkish Technic at Istanbul Airport.
  • Investors are looking ahead to Feb. 26 full-year results and the pace of the share buyback.

Rolls-Royce Holdings plc shares closed at a new 52-week high on Friday, extending a week of record closes as investors sized up fresh civil-aerospace and nuclear headlines and the company’s ongoing share repurchases. The stock ended up 1.65% at 1,293.5 pence, with turnover below its recent average.

The move matters because the market is still trying to pin down how durable the group’s cash generation is as it expands maintenance capacity and pursues longer-dated bets such as small nuclear reactors. A lot of the near-term debate is less about “new engines” and more about service work — the steady fees that come after the sale.

Rolls-Royce is due to publish full-year results on Feb. 26, a date that should bring guidance back into focus after the recent run-up. Traders will be watching for any comment on free cash flow, aftermarket capacity and whether buybacks stay on schedule.

On Thursday, Rolls-Royce and Turkish Technic said ground had been broken on a maintenance, repair and overhaul (MRO) facility at Istanbul Airport, with operations targeted by end-2027. The site is planned to service Trent XWB-84/97 and Trent 7000 engines — used on Airbus A350 and A330neo jets — and is designed for 200 “shop visits” (engine overhauls) a year. Rob Watson, president of civil aerospace at Rolls-Royce, called it “a significant milestone” for its global MRO network, while Turkish Technic chair Ahmet Bolat said the centre is “set to become one of Europe’s largest” for Trent engines. rolls-royce.com

A regulatory filing on Friday showed Rolls-Royce bought 462,606 shares on Jan. 8 under its £200 million share buyback programme, paying a volume-weighted average price of about 1,271 pence. The group said it intends to cancel the shares and has repurchased 2,306,361 shares since the programme began.

Investors are also keeping one eye on the group’s small modular reactor (SMR) push — smaller nuclear units designed to be built largely in factories and assembled on site — even though it is a long-dated story. Great British Energy-Nuclear is working to finalise a contract under which Rolls-Royce would design the first three SMRs planned for Wylfa in north Wales, backed by a 2.5 billion pound government investment, Reuters Events reported; first power is expected in the mid-2030s and Rolls-Royce SMR expects design approval by December 2026. Iolo James, head of communications at the Nuclear Industry Association, said the key challenges include “keeping regulatory approvals on schedule” for a first-of-a-kind project. Reuters

With London markets shut for the weekend, the near-term question is whether the stock can hold above the latest breakout levels when trading resumes. Fresh highs can pull in momentum accounts, but they can also sharpen the urge to take profits ahead of results.

But the set-up has obvious tripwires. Any slip in engine shop capacity build-out, aircraft delivery schedules or cost inflation could pressure service margins, and nuclear timelines remain vulnerable to licensing and financing delays.

When the market reopens, traders will look for the next buyback disclosure and any follow-through from the week’s corporate news. The next fixed catalyst is Rolls-Royce’s full-year results on Feb. 26.

Stock Market Today

  • Pro Portfolio Adds Broadcom and Netflix Shares, Upgrades Broadcom Rating
    June 9, 2026, 10:19 AM EDT. The Pro Portfolio is buying 80 shares of Broadcom (AVGO) at around $405, increasing its holdings to 512 shares (3.4% of the portfolio). It is also purchasing 372 shares of Netflix (NFLX) near $82.35, increasing its stake to 2,107 shares (2.85%). Broadcom's AI chip forecast for H2 2026 is viewed as conservative following a $35 billion private credit deal involving Apollo and Blackstone. The rating for Broadcom is upgraded to One, with a checkpoint price of $330 maintained. Netflix's shares are seen as undervalued despite recent declines, supported by a $25 billion buyback and rising U.S. viewership. Netflix's ad business shows growth potential, reaching 250 million monthly active viewers, reinforcing optimism amidst concerns over consumer spending.

Latest articles

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

9 June 2026
IREN surged 8.9% to $59.19 and was quoted higher premarket after a bitcoin rebound and renewed focus on its pivot to AI cloud infrastructure, but the stock remains exposed to bitcoin swings, heavy spending, and risks tied to its new 800MW South Australia data center project and major contracts with Nvidia and Microsoft.
AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
Rio Tinto stock slides on Glencore merger talks as Feb 5 takeover deadline looms
Previous Story

Rio Tinto stock slides on Glencore merger talks as Feb 5 takeover deadline looms

Lloyds share price clings to £1 as investors eye inflation data and Jan 29 results
Next Story

Lloyds share price clings to £1 as investors eye inflation data and Jan 29 results

Go toTop